Inflammatory bowel diseases (IBD) manifest not only in the gastrointestinal (GI) tract, but also affect joints, skin, eyes, liver, lung, and pancreas. Up to half of patients with IBD have extraintestinal manifestations (EIMs) of IBD. Therapies for intestinal inflammation are not sufficient to treat EIMs such as anterior uveitis, ankylosing spondylitis, and primary sclerosing cholangitis (PSC), which usually occur independent of disease flares. In the October issue of Gastroenterology, Gerhard Rogler et al review the epidemiology, pathophysiology, clinical presentation, and treatment of EIMs in patients with IBD.
Trending
- 5 Top Tips for Colonoscopy (GI & Endoscopy News)
- Scientists uncover gut signals that may improve early cancer detection (Earth.com)
- The AGA Research Foundation awards $2.9 million in digestive health research funding (EurekAlert!)
- The GI hospitalist: A practice-changing health care opportunity (MDedge)
- Virtual Multidisciplinary GI Care Improves Outcomes, Reduces Costs (Gastroenterology Advisor)
- Validation of the American Society for Gastrointestinal Endoscopy’s Complexity Grading System for Endoscopic Procedures (Clinical and Translational Gastroenterology )
- A Randomized Trial of Rifaximin vs Low FODMAP Diet for Symptom Outcomes and Microbiome Changes in Irritable Bowel Syndrome (Clinical GI & Hepatology)
- Aspirin Unlikely to Cut Colorectal Cancer Incidence (Medscape)
